CMS Freezes New Hospice and Home Health Enrollment Nationwide: What the Six-Month Moratorium Means for Owners, Buyers, and Valuations
A measured, owner-focused breakdown of today’s CMS announcement, the data behind it, and the buy-sell window it has created for compliant home health and hospice agencies.
Key Takeaways
- CMS today announced a nationwide, six-month moratorium on new Medicare enrollment applications from hospices and home health agencies, plus certain changes in majority ownership.
- The moratorium does not affect existing providers. Current agencies continue to bill, operate, and critically remain transferable through approved channels.
- For the next six months, the supply of new, billable Medicare-certified agencies is effectively frozen, while buyer demand and private equity dry powder remain elevated.
- The result is a measurable scarcity premium for clean, compliant, established agencies particularly those past the CMS 36-month rule with defensible documentation and stable census.
- This is the most favorable buy-sell window the sector has seen in a decade for owners who are prepared and for buyers who can move on quality assets quickly.
What CMS Announced Today
This morning, the Centers for Medicare & Medicaid Services issued one of the most significant Medicare program-integrity actions in its history: a six-month, nationwide, data-driven moratorium on new Medicare enrollment for hospices and home health agencies. Coordinated with Vice President JD Vance’s Anti-Fraud Task Force, the action halts new applicants from entering these provider categories and also applies to certain changes in majority ownership that have historically been used to obscure beneficial control.
CMS Administrator Dr. Mehmet Oz framed the move as a “shutting the door on fraud,” citing systemic abuse and the need to protect Medicare beneficiaries and taxpayer dollars. The agency reports that, in Los Angeles alone, payments have already been suspended to 773 hospices and 23 home health agencies representing roughly $70 million in suspended funds under the broader anti-fraud effort. Today’s moratorium builds on a similar action against durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) suppliers earlier this year. Three federal moratoria are now active simultaneously.
Existing, compliant providers are not affected in the day-to-day. They continue to deliver care, bill Medicare, and operate as before. What changes is the gate at the front of the system: no new players for six months, paired with intensified investigation and removal of bad actors already inside.
What is and isn’t frozen
- Frozen: All applications for initial Medicare enrollment for new hospices and HHAs, nationwide.
- Frozen: Certain changes in majority ownership where CMS deems the structure is being used to evade oversight.
- Not frozen: Day-to-day operations and billing for existing certified hospices and HHAs.
- Not frozen: Properly structured transactions involving already-enrolled agencies that comply with the CMS 36-month rule and applicable change-in-ownership (CHOW) procedures.
- Heightened scrutiny states: Arizona, California, Georgia, Nevada, Ohio, and Texas, where enhanced enrollment screening was already in place.
Additional published actions referenced in CMS’s release include nationwide unannounced site visits, expansion of the pre- and post-claim review demonstration into Florida, Illinois, Oklahoma, Ohio, North Carolina, and Texas, fingerprinting-based background checks for high-risk HHAs, and a forthcoming publicly available hospice scoring system (the Service and Spending Variation Index) to flag providers with concerning utilization patterns.
Why This Creates an Unusual and Time-Limited Market Window
Healthcare M&A specialists have been signaling a quiet shift since late 2025. According to Mertz Taggart’s Q1 2026 Home-Based Care M&A Report, hospice led all home-based-care sub-sectors with ten closed transactions in the quarter, home care followed with nine, and home health rebounded to six its best quarter in over a year. Headline deals included Kinderhook Industries’ announced acquisition of Enhabit Home Health & Hospice for approximately $1.1 billion at a 10.2x EBITDA multiple. Private equity sponsors have built up an unprecedented amount of dry powder, and many platforms are now five to seven years into their hold periods, with limited partners pressing for liquidity.
Layer today’s moratorium onto that backdrop and the supply-demand equation becomes stark:
- Buyer demand is high and well-capitalized.
- Existing, compliant agencies are now the only way for strategic buyers and PE platforms to enter or expand in a state for the next six months.
- Diligence is tighter than in the 2020–2022 boom but the agencies that pass tighter underwriting are commanding stronger relative pricing.
For owners and buyers who understand the mechanics, this is a window not a permanent state. Federal enrollment moratoria are time-bound. When the freeze lifts (or evolves into a more targeted state-by-state policy), new supply re-enters the funnel. The premium for a turnkey, surveyed, billing-active agency contracts accordingly.
“A nationwide enrollment freeze converts compliance and time-in-market from a back-office cost into a balance-sheet asset. Existing, clean agencies just became scarcer and scarcer assets price differently.”
What This Means for Current Owners
If you own a Medicare-certified home health or hospice agency that is past the 36-month rule, has a clean survey history, and can produce defensible documentation, you now hold something that is by federal action temporarily impossible to replicate. That is not hype. It is a regulatory fact for the next 180 days. We covered the early signals of this shift in our recent analysis on selling your hospice in the 2026 fraud crackdown and our state-specific look at selling a California home health agency during the state-level crackdown. Today’s federal action extends that thesis nationwide.
What changes for sellers in practical terms:
- Buyer urgency is real. Strategic acquirers and PE-backed roll-ups that were planning to enter a new state via de novo licensure now have one option: buy. That tightens timelines on competitive processes and reduces leverage on retrades.
- Compliance is repriced as an asset. Buyers paying through tighter diligence (with EBITDA add-back tolerance compressed from ~20% to 12–15%) are willing to pay more for agencies that can answer questions on the first ask.
- Change-of-ownership scrutiny is higher. CMS specifically named majority-ownership changes as a fraud vector. That means clean, well-papered transactions handled by experienced advisors clear; rushed or opaque structures do not.
- Quality data is now public-facing. The CMS hospice scoring system, HOPE assessment data, and Care Compare are converging into one number buyers can underwrite. Owners who have invested in clinical documentation see the upside; those who have not will see it priced into the offer.
The case for moving now is not “sell at all costs.” It is: if you were already planning to transact in the next 12 to 24 months, the structural backdrop for the next six months is meaningfully more favorable than what existed eight weeks ago. For perspective on what drives multiples in the current environment, see our 2026 Hospice & Home Health Valuation Multiples Report.
What This Means for Buyers
For private equity sponsors, strategic platforms, hospital systems, and family offices targeting the post-acute space, today’s announcement does three things at once. It removes the de novo path as a competitive tool for the next six months. It narrows the supply of acquirable, certified agencies in any given market. And it raises the diligence bar — meaning the meaningful spread now exists between any agency for sale and an agency worth buying.
Buyers should expect:
- Competitive premiums on platform-quality assets. Hospice platforms with strong management, scale, and clean cap exposure already trade in the 7x–10x+ EBITDA range, and high-margin growth platforms can exceed those levels. The moratorium tightens that further.
- Compressed timelines on quality tuck-ins. Smaller agencies that are clean and located in growth markets will see multiple bidders. Mertz Taggart’s data shows hospice and home health add-on activity accelerating into Q2.
- Deeper diligence on every deal. DOJ enforcement activity in California, the LA County board’s recent action targeting more than 4,700 home health and hospice agencies in the county, and OIG’s ongoing hospice portfolio mean every buyer will price compliance risk explicitly.
- Structural protections, not deal kills. As Arnall Golden Gregory has observed, most transactions are not being terminated for compliance issues — they are being repriced through escrows, indemnities, and purchase-price adjustments.
For acquisitive buyers, the right move is to upgrade pipeline discipline now. Quality sourcing, fast and clean diligence execution, and the ability to close credibly is what separates buyers who win in this window from those who watch it pass.
How Valuations Are Likely to Shift
Valuation in this sector is almost always expressed as a multiple of adjusted EBITDA. The multiple itself is a proxy for risk, growth, scale, and compliance posture. Today’s announcement compresses risk perception for established, compliant agencies and expands it for everyone else.
Practical ranges, calmly stated
Industry data on 2026 transactions, including reporting from FOCUS Investment Banking and Mertz Taggart, points to general ranges that look roughly like this:
| Segment | Typical Adjusted EBITDA Multiple | Key Value Drivers |
|---|---|---|
| Independent hospice (small) | ~3x–6x | Census stability, LOS profile, eligibility documentation |
| Regional hospice (mid-market) | ~6x–10x | Scale, payer mix, cap exposure, quality scores |
| Platform hospice | 10x+ (situational) | Geographic density, management depth, strategic synergies |
| Home health (independent) | ~4.5x–8x | Referral diversification, payer mix, staffing model |
| Home health (platform/strategic) | 8x–10x+ (situational) | Scale, value-based care readiness, MA exposure |
Ranges are illustrative based on disclosed market data; individual outcomes vary materially based on agency-specific factors.
The point is not the headline number. The point is that the spread between a prepared agency and an unprepared agency has widened. In a tight-supply market, sellers who can deliver a clean diligence package are paid more (and faster) than sellers who cannot. For an owner-friendly breakdown of how this works, our team maintains a free, plain-English valuation tool at valuemybusiness.com and a deeper methodology walkthrough on how to value your healthcare business.
How Vallexa Advisors Supports Owners and Buyers Through This Window
Vallexa Advisors is a healthcare-focused M&A advisory firm working exclusively with home health, hospice, home care, and behavioral health businesses across all 50 states. Our role is straightforward: translate clinical and operational strength into credible, defensible value… and run a confidential process that protects what you have built.
In this environment, that means three things. First, an accurate valuation grounded in current comparables and the 2026 regulatory backdrop, including HOPE data, survey history, and cap exposure. Second, structured preparation so that diligence does not erode price. Third, access to a vetted buyer network: strategic platforms, PE-backed consolidators, hospital systems, and family offices that can move quickly and credibly. Our fees are success-based. There are no upfront retainers. For a step-by-step on the process, see our guide on how to sell a hospice or home health agency, and for buyers, our overview of healthcare agencies for sale nationwide.
Two Free Resources for This Moment
Educational, branded, and built specifically for the post-moratorium environment.
A 5-section workbook for hospice and home health owners covering regulatory, financial, operational, clinical, and credentialing prep.
A 5-section framework for acquirers covering target identification, compliance red flags, valuation, regulatory diligence, and integration.
Get a Confidential Valuation Range
If you want to understand where your agency stands in the current market quietly, with no obligation… start here. Our intake form is confidential and reviewed by a healthcare M&A specialist, not a sales team.
Frequently Asked Questions
Does the CMS six-month moratorium stop me from selling my existing hospice or home health agency?
No. The moratorium applies to new Medicare enrollment applications and certain changes in majority ownership that CMS flags as fraud vectors. Properly structured sales of established, compliant agencies including standard change-of-ownership transactions handled in line with the CMS 36-month rule continue. The freeze applies to new entrants, not to legitimate ownership transitions.
How does this moratorium affect the value of my agency?
In a tight-supply market, well-prepared and compliant agencies typically command stronger relative pricing because they become harder to replicate. Buyers cannot build a new Medicare-certified agency from scratch during the moratorium, so the only path to entering or expanding in a given market is acquisition of an existing operator. Agencies past the 36-month rule with clean survey history, defensible documentation, and stable census are positioned most favorably.
Should I sell my home health agency or hospice in 2026?
The answer depends on your timeline, financial goals, and the readiness of your business. For owners already considering an exit within the next 12–24 months, the next two to three quarters are structurally more favorable than the prior 18 months: buyer demand is high, PE dry powder is elevated, and new supply is frozen. The right step is a confidential valuation conversation to understand your range before deciding.
What should buyers prioritize during the six-month freeze?
Three things: sourcing discipline (the universe of acquirable agencies just narrowed), tight diligence execution (clean buyers close more deals in a competitive market), and credible structural protections escrows, indemnities, and integration planning that account for the heightened regulatory environment. Buyers who can demonstrate certainty of close win the assets that matter.
What is the CMS 36-month rule and how does it interact with the moratorium?
The 36-month rule restricts certain ownership changes within the first 36 months after a home health agency’s initial Medicare enrollment or most recent change of majority ownership. The moratorium layers on top of this and adds scrutiny to majority-ownership changes that CMS believes are being used to obscure beneficial control. Agencies that are past their 36-month window with clean ownership histories are best positioned for a transaction.
How quickly can I move from a first conversation to a confidential valuation?
A confidential, range-based valuation typically takes one to two weeks from initial intake, depending on financial document availability. There is no upfront fee and no obligation. Use our intake form above, or start with our free valuation tool at valuemybusiness.com to get an initial framework.
Understand Your Position. Then Decide.
The next six months will define market positioning for several years. A confidential conversation with our team takes 30 minutes and costs nothing.
Disclosure: This article provides general market education and does not constitute legal, tax, or financial advice. Cited valuation ranges and transaction data are drawn from publicly available sources including CMS, Mertz Taggart, FOCUS Investment Banking, Stoneridge Partners, the U.S. Department of Health and Human Services Office of Inspector General, and reported industry transactions. Individual results vary materially based on agency-specific factors.
Estimated reading time: 11 minutes
